Cardiovascular disease Archives

News and Trends 2 Feb 2023

Possible drug targets from Korean atherosclerosis research

Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […]

February 2, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Ubiquigent and University of Glasgow to collaborate on drug discovery

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases. Overseen by structural biology experts […]

January 24, 2023 - 3 minutesmins - By Jim Cornall

biomaterials being used in tissue engineering such as repairing a heart

In Depth 10 Jan 2023

Innovative biomaterials are revolutionizing tissue regeneration

Scientists are increasingly realizing the potential of biomaterials to help with many tasks. A key area biomaterials are being used in is tissue engineering and regeneration, something several biotechs and academic labs are currently exploring. Biomaterials are materials or substances designed to function in a biological environment, which may or may not be made of […]

January 10, 2023 - 14 minutesmins - By Helen Albert

cardiology cardiovascular disease heart attack

News and Trends 15 Dec 2022

Cell reprogramming can reverse fibrosis after heart attack

Researchers in Japan may have found a way to repair cardiac damage in patients suffering from chronic heart attack and heart failure. In a study published in Circulation, researchers from the University of Tsukuba have revealed that changing heart cell programming by tweaking the expression of a few key genes can actually reverse the lasting […]

December 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk

U.K.-based Fallouh Healthcare is developing a device to monitor cardiac patients after surgery, which is when a condition, called cardiac tamponade, can strike. The company says patients recovering from heart surgery can be at risk from the life-threatening condition that sees fluid build-up around the heart, strangling its ability to beat properly. Fallouh Healthcare, formed […]

December 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Trial to start for new heart attack drug

A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […]

November 23, 2022 - 3 minutesmins - By Jim Cornall

Interview 18 Nov 2022

How cardioids can usher in the next generation of drug discovery

The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […]

November 18, 2022 - 6 minutesmins - By Omnia Ibrahim

More News! 15 Nov 2022

Sequana Medical has positive results for heart failure therapy drug

Sequana Medical has had some very positive top-line results from a phase 2a study, that the company says reinforces its view that direct sodium removal (DSR) is a potential disease modifying heart failure therapy. The study called SAHARA was testing its first-generation DSR product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients with […]

November 15, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Nov 2022

Proteins identified by FunSel and developed by Forcefield can preserve heart function

Forcefield Therapeutics, has presented positive preclinical data on three proteins identified by it FunSel platform that have the potential to preserve heart function following a heart attack. The company that works with therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction infarction. The paper, Novel Recombinant Cardioprotective Factors Against Myocardial […]

November 7, 2022 - 3 minutesmins - By Liza Laws

Anastasiia Slynko biotech investment 744x368 1

In Depth 11 Oct 2022

The biggest private biotech investments in September 2022

The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […]

October 11, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Oct 2022

Novartis Biome UK Heart Health Catalyst 2022 winners announced

Novartis Pharmaceuticals UK has announced that Xim, creators of Lifelight, and PocDoc are the successful companies of the Novartis Biome UK Heart Health Catalyst 2022, in partnership with Medtronic, RYSE Asset Management, Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. Lifelight and PocDoc will receive support to scale their innovative digital […]

October 6, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

Rivus Pharmaceuticals Inc. has completed a $132 million series B financing round. It was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. The financing will further support clinical advancement of lead candidate HU6, a first-in-class controlled metabolic accelerator (CMA) designed […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cardiovascular disease

Possible drug targets from Korean atherosclerosis research

Ubiquigent and University of Glasgow to collaborate on drug discovery

Innovative biomaterials are revolutionizing tissue regeneration

Cell reprogramming can reverse fibrosis after heart attack

Fallouh Healthcare’s device to give early diagnosis for post-surgery strangulation risk

Trial to start for new heart attack drug

How cardioids can usher in the next generation of drug discovery

Sequana Medical has positive results for heart failure therapy drug

Proteins identified by FunSel and developed by Forcefield can preserve heart function

The biggest private biotech investments in September 2022

Novartis Biome UK Heart Health Catalyst 2022 winners announced

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!